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Abstract
Background: More than one third of adult population in Estonia has problems with elevated blood pressure (BP).
The Hypertension in Estonia (HYPEST) study represents the country’s first hypertension-targeted sample collection
aiming to examine the epidemiological and genetic determinants for hypertension (HTN) and related
cardiovascular diseases (CVD) in Estonian population. The HYPEST subjects (n = 1,966) were recruited across Estonia
between 2004-2007 including clinically diagnosed HTN cases and population-based controls. The present report is
focused on the clinical and epidemiological profile of HYPEST cases, and gender-specific effects on the
pathophysiology of hypertension.
Methods: Current analysis was performed on 1,007 clinically diagnosed HTN patients (617 women and 390 men) aged
18-85 years. The hypertensives were recruited to the study by BP specialists at the North Estonia Medical Center, Centre
of Cardiology, Tallinn or at the Cardiology Clinic, Tartu University Hospital, Estonia. Longitudinal BP data was extracted
retrospectively from clinical records. Current and retrospective data of patient’s medical history, medication intake and
lifestyle habits were derived from self-administrated questionnaire and each variable was examined separately for men
and women. Eleven biochemical parameters were measured from fasting serum samples of 756 patients.
Results: The distribution of recruited men and women was 39% and 61% respectively. Majority of Estonian HTN
patients (85%) were overweight (BMI ≥ 25 kg/m2) and a total of 79% of patients had additional complications with
cardiovascular system. In men, the hypertension started almost 5 years earlier than in women (40.5 ± 14.5 vs 46.1 ±
12.7 years), which led to earlier age of first myocardial infarction (MI) and overall higher incidence rate of MI
among male patients (men 21.2%, women 8.9%, P < 0.0001). Heart arrhythmia, thyroid diseases, renal tubulo-
intestinal diseases and hyperlipidemia were more prevalent in hypertensive women compared to men (P < 0.0001).
An earlier age of HTN onset was significantly associated with smoking (P = 0.00007), obesity (BMI ≥ 30 kg/m2; P =
0.0003), increased stress (P = 0.0003) and alcohol consumption (P = 0.004).
Conclusion: Understanding the clinical profile of HTN patients contributes to CVD management. Estonian
hypertension patients exhibited different disease and risk profiles of male and female patients. This well-
characterized sample set provides a good resource for studying hypertension and other cardiovascular phenotypes.
Background
Hypertension is defined as a physiological condition
characterized by consistently elevated blood pressure
(BP). High BP affects approximately 20 - 30% of the adult
population in modern societies and its prevalence has
been predicted to increase as high as 60% in 2025 [1,2].
Among European countries Estonia stands out with high
prevalence of hypertension, affecting more than one third
of adult population [3]. As high BP is a major risk factor
for cardiovascular morbidity and mortality [4], its early
diagnosis and timely treatment is crucial for postponing
and preventing cardiovascular diseases. In 2005, the mor-
tality from cardiovascular disease among Estonian men
aged < 65 years was three times higher than the average
of European Union member states [3]. The proportion of
hypertensive population in Estonia is increasing hand-in-
hand with its economic status, consistent with studies
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showing that introducing the westernized life style con-
tributes to generally elevated BP levels [1,5]. Despite
major public health problems caused by hypertension,
only limited data are available on its epidemiology, etiol-
ogy and risk factors in Estonian population [6,7]. To pro-
vide a better understanding of lifestyle, environmental
and genetic risk factors leading to elevated BP in Esto-
nian population, we have established the country’s first
hypertension-targeted sample collection HYPEST
(HYPertension in ESTonia).
There is an increasing body of data showing gender-
dependent effects of commonly accepted confounders
(such as age, lifestyle factors or genetic susceptibility)
contributing to the determination of an individual’s BP
[8-12]. For instance, obesity has been shown to be pre-
dominant risk factor for women [11], whereas smoking
enhances the development of hypertension in men [12].
Current report evaluates gender-specific pathophysiology
and risk factors of hypertension in Estonia by comparing
disease and lifestyle profiles of male and female essential
hypertension patients recruited in the framework of the
HYPEST study.
Methods
Study design and recruitment of HYPEST participants
The HYPEST (HYPertension in ESTonia) study has been
approved by the Ethics Committee on Human Research
of University of Tartu (no. 122/13, 22.12.2003; 137/20,
25.04.2005). The study was carried out in compliance
with the Helsinki Declaration and all the participants
have given their written informed consent. The HYPEST
sample collections have been recruited to target the
genetic-epidemiological component of essential hyper-
tension and cardiovascular disease in Estonian popula-
tion. The subjects (n = 1966; age range 18-85 years)
were recruited across Estonia between 2004-2007
including (i) patients with clinically diagnosed essential
hypertension (HTN) (n = 1007) and (ii) a population
controls of long-term blood donors (n = 959). All of the
study participants are of Eastern European ancestry.
Blood samples for DNA extraction and further genetic
analysis were obtained from 1,823 HYPEST individuals
(n = 864 HTN cases; n = 959 population controls). The
genomic DNA of HYPEST participants are stored at
-80°C at the laboratory of the Human molecular genet-
ics research group (headed by Maris Laan), Institute of
Molecular and Cell Biology, University of Tartu. Current
report is only focused on the epidemiology of HYPEST
patients with clinically diagnosed HTN.
Estonian HTN patients (n = 1,007) were recruited by
blood pressure (BP) specialists during patients’ ambula-
tory visits or hospitalization at the North Estonia Medical
Center, Centre of Cardiology, Tallinn or at the Cardiol-
ogy Clinic, Tartu University Hospital, Estonia. These two
main healthcare centers cover major part of Estonia with
premium medical aid (Figure 1). Alternatively, the
patients with clinically diagnosed long-term HTN were
invited to the study by the personnel of cardiology cen-
tres based on subject’s cardiovascular health records at
the clinic. Diagnosis was based on the following Interna-
tional Classification of Diseases 10th Revision (ICD-10)
codes: essential (primary) hypertension (I10), hyperten-
sive heart disease with (congestive) heart failure (I11.0)
and/or hypertensive heart disease without (congestive)
heart failure I11.9).
Collection of blood pressure and epidemiological data
Longitudinal data of systolic and diastolic blood pressure
(BP) readings (before and during antihypertensive treat-
ment) of the HYPEST HTN patients were extracted retro-
spectively from clinical records. The average of each
participant BP readings was used for the analyses in the
current study. Blood pressure measures had been taken
after a rest in sitting position using a conventional mer-
cury column sphygmomanometer and size adjusted cuffs,
and the procedures were performed by trained clinicians
following the standardized protocol [13]. Hypertension
was defined as a systolic BP (SBP) ≥ 140 mm Hg and/or
diastolic BP (DBP) ≥ 90 mm Hg during the healthcare
centre visit. Subjects were asked if they had had treatment
or were being treated currently with antihypertensive
drugs, and the details on used anti-hypertensive drugs
were collected.
The HYPEST study participants filled out a self-admi-
nistered epidemiological questionnaire recording their
past and present health and lifestyle. The questionnaire
included participants’ general demographic data (age,
sex, nationality, place of residence), lifestyle factors
(tobacco and alcohol consumption, preferences of food
consumption), physical activity, stress, health status and
medical records of the subject. Additionally, self-reported
familiar disposition to cardiovascular disease was
recorded. Personal medication, including past and cur-
rent prescription and over-the-counter drugs were col-
lected based on self-reported data and available clinical
records. Additionally, for female participants’ data
regarding their reproductive history (number of children,
pregnancy complications and hormonal replacement
therapy) was collected. Information about smoking status
included the previous and current smoking status as well
as the amount of tobacco smoked (number of cigarettes,
cigarillos, cigars or pipes), age of beginning and quitting
(for former smokers). Data on alcohol consumption
habits during lifetime included the drinking status and
the volume of consumed alcohol (wine, beer and spirit)
during the week. Body mass index was based on partici-
pant’s body weight and height values during recruitment
and was defined as weight/height2. Additionally, self-
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reported data were documented for birth weight, birth
height and weight at age 18 years. Physiological stress
was rated based on self-reported information: (i) no
stress or occasional short stress episodes during their life;
(ii) exposure to regular stress.
Analysis of serum biomarkers
Among the enrolled HTN patients (n = 1,106) 756 indi-
viduals (484 women/272 men) agreed to provide blood
samples for serum biomarker analysis. The venous
blood samples for clinical chemistry analysis were drawn
in the morning after an overnight fast. Clinical chemis-
try assays were performed using standardized assays
(Cobas Integra 800® analytical platform, Roche Diagnos-
tics, Inc. USA) applied at the accredited hospital labora-
tories in Tartu (United Laboratories, Tartu University
Clinics) and in Tallinn (Diagnostic Division Laboratory,
North Estonia Medical Center). The following para-
meters from serum were estimated: (1) Sodium (S-Na)
[mmol/l], (2) Potassium (S-K) [mmol/l], (3) Urea (fS-
Urea) [mmol/l], (4) Creatinine (fS-Crea) [μmol/l], (5)
Uric acid (S-UA) [μmol/l], (6) Albumin (S-Alb) [g/l], (7)
Cholesterol (fS-Chol) [g/l], (8) Triglycerides (fS-Trigl)
[mmol/l], (9) HDL-Cholesterol (fS-HDL-C) [g/l], (10)
LDL-Cholesterol (fS-LDL-C) [g/l] and (11) C-reactive
protein (fS-CRP) [mg/L]. The tests of the serum
biomarkers have been accredited by Estonian Accredita-
tion Center [14] according to the standards of the
European co-operation for accreditation [15]. Measure-
ment uncertainty was estimated using EURACHEM
guidelines [16]. Measurement uncertainty is defined as
the parameter associated with the result of a measure-
ment that characterizes the dispersion of the values that
could reasonably be attributed to the measuring (e.g. the
concentration of a biomarker). Additional aliquots were
stored at -80°C.
Statistical analysis
Statistical analysis was performed using Statistical Analy-
sis System (SAS) software (version 9.1) (SAS Institute
Inc., Cary, North Carolina, USA). Variables were esti-
mated separately for men and women, and significance of
gender differences was compared using Mann-Whitney
U-test (two-sided) for quantitative (not normally distrib-
uted) and categorical variables. Gender comparison of
SBP and DBP without and under antihypertensive treat-
ment was performed by analysis of covariance
(ANCOVA) adjusted by median age of each patient at BP
readings during pre-treatment or medication period,
respectively. Fisher’s exact test was used for calculating of
frequency differences. Statistical significance was assessed
for p < 0.05.
Figure 1 Physical map of Estonia (~45000 km2) and two recruitment centers: North-Estonian Regional Hospital, Tallinn representing
Northern, North-Eastern, South-Western and Western (including largest islands) parts of Estonia; University of Tartu Clinics, Tartu,
representing Central, South-Eastern and Southern parts of Estonia.
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Results
Recruitment and demographic data of the study
population
Estonian patients with clinically diagnosed essential
hypertension (HTN) were invited to the HYPertension
in ESTonia (HYPEST) study by the cardiology centers
at the University of Tartu Clinics, Tartu and North-
Estonian Regional Hospital, Tallinn. Detailed information
on recruitment stages and response rates is provided in
Table 1. Among 2,383 invited patients with clinically
diagnosed HTN (men, n = 977; women, n = 1406), 1,106
subjects (46.4%; men, n = 424; women, n = 682) gave
written informed consent. The response rate among
hypertensive women was slightly higher compared to
male patients (48.5% vs. 43.4%, respectively). Eventually,
1,007 HTN patients returned filled self-administrated
epidemiological questionnaires and 756 of them (75.1%)
also agreed to provide blood samples for serum biomar-
ker analysis. The recruited Estonian HTN patients
covered a wide range of age groups (18-85 years; mean
57.22 ± 11.15 years; Table 2).
The final distribution of genders among HYPEST cases
with self-administrated epidemiological data was 617
women/390 men (61.3%/38.7%). At the recruitment, an
average female patient was 4 years older than a partici-
pating male patient (58.9 ± 9.6 vs. 54.5 ± 11.2 years;
Table 2). Expected significant differences between men
and women were detected for baseline anthropometric
characteristics (mean height 177.6 vs.162.9 cm; mean
weight 94.2 vs. 80.6 kg, respectively) and for self-reported
birth height and weight (Table 3). Majority of Estonian
HTN patents (85%) were classified as overweight (BMI ≥
25 kg/m2), mean BMI was estimated as high as 30.4 ±
5.5 kg/m2 for women and 29.8 ± 5.0 kg/m2 for men.
Diagnosis and treatment of hypertension
At the recruitment, the mean duration of hypertension
among in HYPEST male and female HTN patients was
similar, 13.9 ± 12.5 and 13.1 ± 10.8 years, respectively
(Table 4). However, the male patients had been on average
~5 years younger compared to hypertensive women at the
clinical diagnosis of hypertension (40.5 ± 14.5 vs. 46.1 ±
12.7 years respectively, P < 0.0001). Retrospective BP read-
ings (range 1-29 measurements/subject) had been docu-
mented for 708 HTN patients (248 men/460 women)
during mean 2.3 years (range 1-17 years). BP values during
antihypertensive treatment period were available for
528 (182 men/346 women) and the pre-diagnosis (without
treatment) BP values were available for 344 patients
(124 men/220 women). For 272 patients (101 men/171
women) both, pre-treatment and under medication BP
values had been clinically recorded. BP records under anti-
hypertensive treatment had been documented with ≥ 3
readings/subject for 328 patients and ≤ 2 readings/subject
for 200 patients (mean 3.49 ± s.e.m. 0.11; median 3.0),
whereas majority of available pre-treatment data (82% of
patients) was represented by up to two BP readings/sub-
ject (mean 1.81 ± s.e.m. 0.01; median 1.0).
The mean baseline systolic (SBP) and diastolic blood
pressure (DBP) of recruited patients regardless their anti-
hypertensive treatment status, was 143.2 mmHg (range
131.8 - 156.7 mmHg) and 87.1 mmHg (range 80.3 - 94.6
mmHg), respectively. Recruited female patients exhibited
a trend for higher SBP compared to men (144.6 ± 18.7
mmHg vs. 140.5 ± 17.3 mmHg; P = 0.06; Table 4). Since
BP has a tendency to rise with the age, the observed dif-
ferences among sexes may reflect older age of female
compared to male patients (Table 2). Alternatively, this
may result from the lower efficacy of BP lowering
Table 1 Recruitment strategy and efficacy of hypertension patients across Estonia
North-Estonian Regional Hospitala University of Tartu Clinicsb All
Recruitment stage Invited
(n)
Agreed
(n)
Responded
(%)
Invited
(n)
Agreed
(n)
Responded
(%)
Invited
(n)
Agreed
(n)
Responded
(%)
Information and consent letters
total 1221 590 48.3 1162 516 44.4 2383 1106 46.4
men 509 251 49.3 468 172 36.8 977 424 43.4
women 712 339 47.6 694 344 49.6 1406 682 48.5
Epidemiological questionnaires
total 590 510 86.4 516 497 96.3 1106 1007 91.1
men 251 232 92.4 172 160 93.0 424 390 92.0
women 339 278 82.0 344 337 98.0 682 617 90.5
Blood serum samples
total 510 398 78.0 497 358 72.0 1007 756 75.1
men 232 174 75.0 160 100 62.5 390 273 70.0
women 278 222 80.6 337 261 77.4 617 484 78.4
a Regional coverage: Northern, North-Eastern, South-Western (including the largest island Saaremaa) of Estonia (Figure 1); b Regional coverage: Central, South-
Eastern and Southern- Estonia (Figure 1); n - number of subject.
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treatment among Estonian women compared to men,
described previously in a report of the Estonian Society
of Hypertension [7].
Among the enrolled Estonian HTN patients (n =
1,007) 588 individuals were knowledgeable about the
details of their prescribed antihypertensive treatment.
Majority of them (93%) was currently taking anti-hyper-
tensive medication, 7% had temporarily quitted medica-
tion. Across all recruited HTN patients the mean period
of antihypertensive treatment was 42.5 ± 40.6 months.
The number of different prescribed medicines per
patient during the treatment period was as high as 3.4 ±
1.7. The most frequent choice for the first prescribed
medicine had been a b-blocker (33.6% of cases) followed
by ACE-inhibitors (27.7%) and Ca-antagonists (24.5%).
For 16.7% of the patients the antihypertensive treatment
was launched by the prescription of several drugs.
Associated clinical conditions (ACC): self-reported data
Consistent with the study group formation based on
diagnosis of HTN, 79% of participants (81% of women,
76% of men) had complications in cardiovascular system.
Among the Estonian HTN patients recruited to the
HYPEST study (n = 1,007), 119 individuals had experi-
enced myocardial infarction (MI), 53 subjects had suf-
fered from stroke and 120 had also diabetes (Table 5).
Notably, the onset and prevalence of several clinical con-
ditions showed considerable sex-biased differences
(Table 5, 6). The first MI had occurred an average ~ 5
years earlier in male patients compared to females
(51.4 ± 8.7 vs. 55.5 ± 8.0 years, respectively; P = 0.02). In
total, the incidence of MI among hypertensive men was
more than twice as high as in women (21.1% vs. 8.9%; P <
0.0001). This may be related to earlier onset of hyperten-
sion in men in general (Table 4). A trend of association
was observed between earlier onset of HTN and
increased number of documented MI incidences per
patient (Pearson’s correlation r = -0.12; P < 0.01). The
diagnosis of diabetes showed similar trend of earlier
onset in male HTN patients (47.8 ± 13.0 vs. 52.4 ± 10.8
years; P = 0.07), whereas no differences among sexes
were estimated in disease prevalence (women: 14.6%,
men 12.9%). Hypertensive women suffered significantly
more from heart arrhythmia (76.7 vs. 61.0%; P < 0.0001).
Table 3 Gender differences in anthropometric variables among Estonian hypertension patients
Male Female
Variable Mean ± SD
(95% CI)
Median Mean ± SD
(95% CI)
Median P-valuee
for gender comparison
Height (cm) 177.6 ± 7.4
(176.8-178.3)
178 162.9 ± 5.7
(162.5-163.4)
163 < 0.0001
Weight (kg) 94.2 ± 17.7
(92.4-96.0)
92 80.6 ± 15.5
(79.4-81.8)
80 < 0.0001
BMI (kg/m2) 29.8 ± 5.0 (29.3 ± 30.3) 29.1 30.4 ± 5.5
(29.9-30.8)
29.7 0.12
Birth height a (cm) 51.4 ± 1.9
(51.0-51.7)
51 50.4 ± 2.5
(50.0-50.8)
50 < 0.0001
Birth weightb
(g)
3680.4 ± 572.2 (3583.0-3777.9) 3600 3411.4 ± 650.6 (3321.9-3501.0) 3500 < 0.0001
Weight at 18 years c (kg) 70.7 ± 10.0
(69.6-71.9)
70 56.8 ± 8.4
(56.0-57.5)
56 < 0.0001
a n = 98 men; n = 139 female; b n = 135 men; n = 205 female; c n = 302 men; n = 487 female;
e Mann-Whitney U test; SD - standard deviation; CI - confidence interval; Highly significant P-values (< 0.0001) have been indicated in bold.
Table 2 Number, age- and gender-specific distribution of recruited patients with clinically diagnosed hypertension in
HYPEST study
Age groups (years) All HTN patients (%) Men (%) Women (%)
< 30 10 (1.0) 8 (2.1) 2 (0.3)
30-39 43 (4.3) 22 (5.8) 21 (3.4)
40-49 152 (15.1) 81 (20.8) 71 (11.5)
50-59 375 (37.2) 157 (40.3) 218 (35.3)
60-69 325 (32.3) 82 (21.0) 243 (39.4)
≥ 70 102 (10.1) 40 (10.3) 62 (10.0)
Total recruited 1,007 390 617
Mean age at recruitment (± SD) 57.2 (± 11.2) 54.5 (± 11.2) 58.9 (± 9.6)
HTN - hypertension; SD - standard deviation.
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No gender effect was detected for the age of incidence of
the first stroke as well as for the frequency of stroke
(women: 6.0%, men 7.1%; Table 5, 6).
Among other diseases, the HYPEST hypertensive men
experienced 3-fold higher frequency of renal failure
(women: 2.4%, men 8.9%; P < 0.0001; Table 6), whereas
hypertensive women suffered significantly more (P <
0.0001) from renal tubulo-intestinal diseases (16.8% vs.
2.8%), thyroid diseases (22.1% vs. 4.2%) and hyperlipide-
mia (46.1% vs. 30.1%).
Serum biomarkers
Majority of the HYPEST HTN patients (n = 756; 272
men/484 women) provided blood samples for the analyses
of 11 serum biomarkers (detailed in Methods; Table 7).
Consistent with disturbances in their cardiovascular sys-
tem, HTN patients irrespective of sex exhibited elevated
total cholesterol (mean value for men 5.5 g/l and for
women 5.6 g/l) and LDL-cholesterol (mean value for men
3.7 g/l and for women 3.9 g/l) levels compared to normal
laboratory reference range (< 5.0 g/l and < 3.0 g/l for total
and LDL-cholesterol, respectively). For seven serum bio-
markers the distribution of measured concentrations was
statistically different between genders (P≤0.01). Urea, uric
acid, creatinin and albumin levels were higher in men
compared to women. Conversely, women exhibited higher
concentration of K+, total cholesterol and HDL-cholesterol
levels.
Characteristics of life style risk factors
The analysis of current and retrospective lifestyle factors
of the enrolled Estonian HTN patients was performed
based on self-reported data. In general, the hypertensive
study participants appear to be knowledgeable in moni-
toring their everyday food content and physical activities,
as well as in restricting alcohol consumption and smok-
ing (Table 8). Still, hypertensive women tend to follow
healthier food, drinking and smoking habits (P < 0.0001),
Table 5 Characteristics of associated clinical conditions (ACC) among Estonian hypertension patients
Male Female
Parameter n Mean ± SD
(95% CI)
Median n Mean ± SD
(95% CI)
Median P-valuea
for gender
comparison
Age of first stroke (y) 23 56.2 ± 10.3
(51.8-60.7)
53 30 57.2 ± 8.2
(54.1-60.3)
56 0.41
Age of first infarction (y) 70 51.4 ± 8.7
(49.4-53.5)
51 49 55.5 ± 8.0
(53.2-57.8)
56 0.02
Age of beginning of diabetes (y) 38 47.8 ± 13.0
(43.5-52.1)
50 82 52.4 ± 10.8
(50.0-54.8)
54.5 0.07
Duration of diabetes (y) 38 9.1 ± 10.9
(5.5-12.7)
5 82 8.0 ± 7.6
(6.3-9.6)
5.3 0.99
a Mann-Whitney U-test; n - number of patients; SD - standard deviation; CI - Confidence Interval.
Table 4 Hypertension diagnosis and profile of HYPEST patients
Male Female
Mean ± SD
(95% CI)
Median Mean ± SD
(95% CI)
Median P-value
for gender comparison
Diagnosis of hypertension (HTN)
Diagnosis age (y) 40.5 ± 14.5
(38.8-42.2)
43 46.1 ± 12.7
(44.9-47.2)
48 < 0.0001c
SBP (mmHg) without treatmenta 156.5 ± 19.9 (152.9-160.0) 155 160.1 ± 21.2
(157.2-162.9)
158 0.28d
DBP (mmHg) without treatmenta 97.2 ± 13.4
(94.8-99.6)
99.5 95.1 ± 12.8
(93.4-96.8)
94 0.43d
Hypertension profile at recruitment into HYPEST study
Duration of hypertension (y) 13.9 ± 12.5
(12.4-15.4)
9 13.1 ± 10.8
(12.2-14.1)
10 0.92c
SBP (mmHg) under treatmentb 140.5 ± 17.3 (138.0-143.1) 140 144.6 ± 18.7
(142.6-146.6)
142 0.06d
DBP (mmHg) under treatmentb 86.6 ± 11.0
(85.0-88.2)
85 87.4 ± 10.6
(86.3-88.5)
87.5 0.28d
a BP determined at diagnosis of HTN before prescription of antihypertensive medication, n = 344 (124 men/220 women); b HTN patients with antihypertensive
treatment n = 528 (182 men/346 women); c Mann-Whitney U test; d age-adjusted Analysis of covariance (ANCOVA); SD - standard deviation; CI - confidence
interval
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whereas male patients invest more to regular exercise
(P = 0.0091). The proportion of never-smokers (non-
smokers at diagnosis of HTN excluding previous smo-
kers) was substantially higher in women (75.5% vs.
24.9%) and there were more smokers among men at the
diagnosis of hypertension (36.1% vs. 10.8%; P < 0.0001)
and at the recruitment (19.6% vs. 8.6%, P < 0.0001)
(Table 8). Notably, 69.2% of Estonian HTN patients
reported to have experienced regular stress.
We attempted to estimate the role of individual lifestyle
risk factors (smoking, BMI, stress and alcohol consump-
tion) on the age of onset of hypertension (Figure 2). All
these risk factors were shown to significantly affect the
age of hypertension onset (P < 0.005). The most signifi-
cant effect was detected for smoking, which strongly
enhanced the development of HTN. Among non/pre-
vious smokers (smoking status at the diagnosis of HTN),
the age of the diagnosis of HTN (47.5 ± 13.8 years) was
approximately 5 years later (P = 0.00007) compared to
the subgroup of regular smokers (42.0 ± 12.3 years).
Discussion
In Estonia, cardiovascular diseases (including hyperten-
sion) are the most common cause of death both in men
and women [3]. Despite the fact that the prevalence of
cardiovascular diseases as a cause for loss of life years has
decreased significantly during the past decade in Estonia,
it is still nearly two times higher than in other European
countries [17]. A clear need exists for a more systematic
understanding of the epidemiology, diagnosis, and man-
agement of hypertension in Estonia. We established
HYPEST sample collection, which provides a good
resource for studying genetic-epidemiological component
of HTN in Estonian population. This report is focused
on the comparative analysis of disease and lifestyle pro-
files of Estonian male and female hypertensive patients,
Table 6 Frequencies of self-reported clinical conditions profile in men and women
Variable Men (%) Women (%) P-valuea
Diseases of cardiovascular system
Myocardial infarction 21.1 8.9 < 0.0001
Stroke 7.1 6.0 0.50
Ishaemic heart disease 29.2 33.3 0.21
Heart arrhythmia 61.0 76.7 < 0.0001
Other diseases of the circulatory system 15.6 19.4 0.40
Diseases of genitourinary system
Glomerular diseases 0.7 1.6 0.49
Renal tubulo-intestinal diseases 2.8 16.8 < 0.0001
Renal failure 8.9 2.4 0.0001
Urolithiasis 8.5 9.3 0.79
Other disorders of kidney and ureter 5.2 9.0 0.06
Other diseases of urinary system 0.3 1.3 0.25
Endocrine, nutritional and metabolic diseases
Diabetes 12.9 14.6 0.50
Thyroid disease 4.2 22.1 < 0.0001
Hyperthyroidism 1.9 13.9 < 0.0001
Hypothyroidism 2.2 8.0 < 0.0001
Hyperlipidaemia 30.1 46.1 < 0.0001
Other endocrine and metabolic diseases 2.5 0.7 0.17
Diseases of the digestive system 27.9 21.6 0.20
Other complications
Asthma 5.6 7.1 0.42
Diseases of the musculoskeletal system and connective tissue 33.3 42.9 0.08
Neoplasms 6.5 11.4 0.15
Diseases of nervous system 8.2 11.7 0.38
Mental behavioural disorders 2.5 3.3 0.76
Diseases of the respiratory system 13.1 10.3 0.39
Diseases of the skin and subcutaneous tissue 1.6 2.6 0.73
Other diseases 11.5 22.0 0.02
a Gender comparison, probability by Fisher’s Exact test. Highly significant P -values (< 0.0001) have been indicated in bold.
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Table 7 The profile of serum biomarkers
Male (n = 272) Female (n = 484)
Serum
biomarker
Mean ± SD
(95% CI)
Mean ± SD
(95% CI)
Reference valuesa P-value for gender comparisonb
Na+
(mmol/l)
140.4 ± 2.2
(140.1-140.7)
140.3 ± 4.5
(139.9-140.7)
136-145 0.29
K+
(mmol/L)
4.3 ± 0.4
(4.3-4.4)
4.7 ± 6.1
(4.2-5.3)
3.5-5.1 0.01
Urea
(mmol/L)
6.1 ± 2.0
(5.8-6.3)
5.7 ± 1.6
(5.5-5.8)
≤65 yrs < 8.3
> 65 yrs < 11.9
0.009
Creatinine (μmol/L) 88.5 ± 35.8
(84.2-92.7)
68.4 ± 29.2
(65.7-71.0)
M 62-106
F 44-80
< 0.0001
Uric Acid (μmol/L) 391.6 ± 84.0
(381.5-401.6)
317.8 ± 81.1
(310.6-325.1)
M 202-417
F 143-339
< 0.0001
Albumin
(g/L)
44.6 ± 3.4
(44.2-45.0)
43.7 ± 2.8
(43.4-43.9)
35.0-52.0 < 0.0001
Cholesterol
(g/l)
5.5 ± 1.1
(5.4-5.6)
5.6 ± 1.2
(5.6-5.9)
< 5.0 0.007
Triglycerides (mmol/L) 1.9 ± 1.9
(1.7-2.1)
1.7 ± 1.5
(1.6-1.9)
< 2.0 0.23
HDL-Choles-terol (g/l) 1.4 ± 0.4
(1.3-1.4)
1.6 ± 0.4
(1.5-1.6)
> 1.0 < 0.0001
LDL-Choles-terol (g/l) 3.7 ± 1.0
(3.6-3.8)
3.9 ± 1.0
(3.8-3.9)
< 3.0 0.08
C-reactive Protein (mg/L) 3.8 ± 7.8
(2.7-4.8)
3.3 ± 5.0
(2.8-3.8)
< 5.0 0.92
ahttp://www.kliinikum.ee/yhendlabor/index.php?option=com_content&view=article&id=48&Itemid=37; b Mann-Whitney U test; M - male; F - female; SD - standard
deviation; CI - Confidence Interval; yrs - years; significant P-values (< 0.01) have been indicated in bold.
Table 8 Gender differences of life style factors HYPEST hypertensive patients
Self-reported lifestyle factor Male (%) Female (%) P-value for gender comparisonb
Status at recruitment
Current smoking 19.6 8.6 < 0.0001
Alcohol consumption more
than once a week
22.1 2.1 < 0.0001
No current alcohol drinking 9.7 25.2 < 0.0001
Follows low caloricity 25.0 46.7 < 0.0001
Follows low fat content 54.4 74.8 < 0.0001
Follows low salt content 48.6 61.5 < 0.0001
Follows low sugar content 45.3 57.1 0.0004
Special diets 5.0 6.2 0.31
Physical loading at work (medium/high) 32.6 28.2 0.32
Physical activity at leisure
time (> 2 times/week)
62.0 55.0 0.009
Retrospective data
Smokers at diagnosis of hypertension 36.1 10.8 < 0.0001
Non-smokers at diagnosis of hypertension 44.4 82.4
Previous smokers (at diagnosis) 19.5 6.9
Regular sport in childhood 73.0 50.4 < 0.0001
Intensive sports in childhood 27.6 13.1 < 0.0001
No or occasional stressa 30.8 30.8 1.0
Expose to regular stressa 69.2 69.2 1.0
Periods of malnourishmenta 30.0 36.1 0.06
a during lifetime; b Fisher’s Exact test. Highly significant p-values (< 0.0001) have been indicated in bold.
Org et al. BMC Cardiovascular Disorders 2011, 11:55
http://www.biomedcentral.com/1471-2261/11/55
Page 8 of 12
who were enrolled during the HYPEST study from 2004
to 2007. Patients were recruited in two main healthcare
centers covering major part of Estonia. In most published
epidemiological studies BP measurements were con-
ducted during a single visit [1]. In HYPEST study, the
diagnosis of hypertension was defined by cardiologist and
relies on several consecutive BP measurements. The
overall fraction of female patients among invited (~ 59%)
and recruited (61%) study participants was higher com-
pared to male hypertensives. This bias was introduced
due to higher proportion of women with available clini-
cally diagnosed essential hypertension records in partici-
pating centers. Also, the age distribution is different
between genders; with much less men belonging to the
age group 60+. The lower proportion of elderly male
patients could be influenced by the fact that, in Estonia,
the mean life expectancy in men is considerably shorter
than in women (67.1 years in men vs 78.7 years in
women), which makes it difficult to include older men
into the study [3].
Figure 2 Significant correlations (Mann-Whitney U-test) between the age at the onset of hypertension (HTN) and self-reported
lifestyle risk factors. The epidemiological questionnaires documented lifestyle factors at the recruitment, including also retrospective data for
the lifetime. Smokers and non-smokers were defined based on smoking status at the diagnosis of HTN. Obesity was defined as BMI ≥ 30 kg/m2.
Life-long alcohol consumption habits were classified as: less than once a week (no or restricted alcohol intake) and more than once a week.
Stress factor was divided into subgroups exhibiting (i) regular or (ii) no/occasional stress. The first group included individuals who reported
regular stress during recruitment or had experienced regular stress period during lifetime. The second group consisted of individuals who had
never experienced stress or had reported only occasional stress episode during their life.
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Men and women differ in the pathophysiology, risks
and treatment of essential hypertension. The prevalence
of hypertension increases with age and is higher among
men than women before the age of 55 years, but slightly
higher among women thereafter [18]. Similar trend was
detected in current study, where the age of hypertension
diagnosis in male patients was around 5 years earlier
compared to female cases. The higher age of female
population could reflect, in part, the protective hormone
effect before menopause, which could postpone the
onset of hypertension [10,19]. The elevated blood pres-
sure is a high risk factor for later cardiovascular and
renal diseases and therefore it was not surprising that
patients had markedly higher prevalence of cardiovascu-
lar diseases compared to general population [20]. The
most common self-reported cardiovascular problem for
both sexes was heart arrhythmia, followed by ischemic
heart disease. The observed earlier occurrence of the
first myocardial infarction as well as higher number of
incidences in male patients is probably related to the
earlier onset of hypertension in men. This is consistent
with previous studies done in Estonia, showing that in
case of men, cardiovascular diseases occur earlier com-
pared to women [21,22]. Problems with cardiovascular
system were also reflected in serum biomarker analysis,
showing increased total and LDL-cholesterol levels
among patients compared to normal laboratory refer-
ence range. In general, women seem to be keener to
monitor their health compared to men, which is
reflected in higher number of reported incidences of
other diseases in the self-reported questionnaire.
It is widely known that lifestyle behaviors such as redu-
cing weight and alcohol intake, quitting smoking,
increasing physical activity and eating a healthy diet are
related to the prevention and control of elevated blood
pressure [22,23]. Current study clearly demonstrates that
reducing the conventional lifestyle risk factors could
delay the age of hypertension onset. This effect was most
significant with smoking status, which is concordant with
recent study done in Japanese population [12]. Another
generally accepted risk factor for increased blood pres-
sure is elevated BMI [8,11]. One limitation of the current
study is unavailable BMI data at the time of HTN diagno-
sis. Thus, to assess the effect of excess weight on the
onset of hypertension, we used in our analysis stringent
criteria to subdivide HYPEST HTN patients based on
BMI data collected at the recruitment (obese ≥ 30 kg/m2
and non-obese < 30 kg/m2). In general, study participants
appeared to be aware of the risk factors and seemed to
consciously reduce them in their everyday life. For exam-
ple, among hypertensive patients the number of current
smokers is two times lower compared to general Estonian
population [24,25]. Furthermore, almost half of the male
patients who reported current smoking habit during the
diagnosis of hypertension had quit smoking after
diagnosis.
Unfortunately excessive weight gain shows increasing
trend in general Estonian population, which is also
reflected in HYPEST data [3,24,26]. The majority of
HYPEST patients are overweight (BMI ≥ 25 kg/m2) and
this proportion is approximately 20% higher than aver-
age in 40-70 years old Estonian people [27]. Observed
mean values for BMI among the recruited HYPEST
patients were higher (29.8 ± 5.0 kg/m2 for males; 30.4 ±
5.5 kg/m2 for females) than respective means of age and
gender in general Estonian population (27.8 ± 4.2 kg/m2
for males; and 28.4 ± 5.6 kg/m2 for females) in age
group 50-60 years [26]. Probably problems with over-
weight among HTN patients have encouraged them to
pay more attention to the everyday diet as well on the
physical activity. However, although dietary habits in
Estonia have improved during the last decade, one third
of all participated patients (33.72%) notified periods of
malnourishment during their lifetime. This could be
explained by the fact that most of study participants
belong to age groups where they could have been influ-
enced by the period of Second World War. Maternal
diet during the pregnancy and/or poor nutrition in early
childhood could both influence the development of car-
diovascular disease (including hypertension) in adult-
hood [28]. Finally, the hypertensive patients, who
participated in the HYPEST study show awareness of
their health conditions and have been responsive in
adopting healthy lifestyle recommendations given by
their physicians.
The present study has certain limitations that should be
taken into account for interpretation of the results. First,
the retrospective self-reported epidemiological data may
be biased and tend to exaggerate the occurrence of events.
Second, the non-equal distribution of men/women
patients as well as the age distribution among sexes might
affect the gender-related differences and bias the estimate.
In addition, the study sample is only representative of
volunteers and findings may therefore not be generalized
to all Estonian hypertension patients. Finally, the retro-
spective BP data extracted from patient’s clinical records
were measured with different clinical settings (investiga-
tors, devices, laboratories) and thus, certain undefined
measurement variability could have been introduced into
the estimates. Despite these limitations, the present study
gives a profile of Estonian hypertensive patients by analyz-
ing considerably larger number of subjects than earlier
investigations [6,7,24].
Conclusions
In summary, the current study characterizes the profile
of HTN patients in Estonia. We compared disease and
lifestyle parameters of male and female hypertensive
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patients recruited for the HYPEST study. Our findings
are in agreement with published studies, which have
revealed gender-specific differences in (i) the age at
HTN onset, (ii) HTN risk factors affecting males and
females, and (iii) secondary complications of the disease.
HYPEST sample collection, combining the clinically
diagnosed HTN cases (n = 1,007) and population-based
controls across Estonia (n = 959) is a valuable source
for further epidemiological as well as genetic studies of
hypertension [29-37].
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